Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,918 shares of the company’s stock after selling 322 shares during the quarter. Yousif Capital Management LLC’s holdings in Protagonist Therapeutics were worth $885,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Protagonist Therapeutics by 749.2% in the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock valued at $25,000 after purchasing an additional 487 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Protagonist Therapeutics during the fourth quarter worth approximately $38,000. Exchange Traded Concepts LLC purchased a new stake in Protagonist Therapeutics in the third quarter valued at approximately $43,000. CWM LLC lifted its stake in Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after buying an additional 1,147 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Protagonist Therapeutics in the third quarter valued at approximately $69,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Suneel Gupta sold 103,437 shares of Protagonist Therapeutics stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the completion of the transaction, the insider now directly owns 256,174 shares of the company’s stock, valued at approximately $11,794,250.96. The trade was a 28.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $46.96, for a total value of $3,687,299.20. Following the completion of the sale, the chief executive officer now directly owns 435,208 shares in the company, valued at $20,437,367.68. This trade represents a 15.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 207,957 shares of company stock worth $9,611,739 in the last 90 days. 5.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PTGX has been the subject of several research reports. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. BMO Capital Markets started coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $62.00 target price for the company. JMP Securities reissued a “market outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. The Goldman Sachs Group initiated coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set a “neutral” rating and a $47.00 price objective for the company. Finally, StockNews.com downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $38.67 on Friday. The business’s fifty day moving average price is $38.68 and its 200 day moving average price is $41.81. The firm has a market capitalization of $2.30 billion, a PE ratio of 14.54 and a beta of 2.22. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $48.89.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.